Policy Center for Maternal Mental Health’s Post

I’m excited to share our newest publication: "Risk Factors of Overdose in Maternal Patients with Opioid Use Disorder: A Scoping Review." While opioid-related overdoses are a leading cause of maternal mortality in the United States, there is a lack of comprehensive data on the risk factors specific to pregnancy and the postpartum period. Via this review, we aim to identify key factors that could inform more effective strategies and healthcare interventions to prevent opioid use during pregnancy. Read more here! https://lnkd.in/d89YnrQw

Obesity poses significant risks to pregnancy outcomes, including an increased likelihood of miscarriage and pregnancy complications. As more women turn to weight-loss medications like Ozempic in preparation for pregnancy, it becomes imperative to understand the potential impacts on fetal health. While these medications may offer benefits in weight management, the lack of data on their safety during pregnancy underscores the need for a comprehensive approach to preconception care. Healthcare providers must navigate the delicate balance between achieving weight loss goals and minimizing potential risks to the fetus. Dr. Akua Nuako rightly points out the challenges faced by individuals in this journey, emphasizing the importance of informed decision-making and tailored guidance in navigating these unknowns. It's crucial to prioritize research and education surrounding the use of weight-loss medications in preconception care to ensure healthier pregnancies and maternal outcomes. #weightloss #obesity #pregnancy #preconception https://lnkd.in/eWiAwyhy

This article emphasizes the necessity of considering the effects of weight-loss medications on maternal and fetal health during preconception, advocating for informed decision-making and personalized guidance. Dr. Nuako's insights underscore the crucial need for a holistic approach to addressing obesity in preconception and pregnancy, ensuring comprehensive care for both mother and baby. #pregnancy #weightloss #fetalhealth #maternalhealth

For a long time, methadone was the only acceptable MAT in pregnancy. Now ASAM, ACOG & others recognize that buprenorphine is safe, and in fact, to basically continue whatever is working. But for a long time, there was a concern that naloxone could have adverse fetal effects, so the buprenorphine-only product (previously Subutex) was preferred to the buprenorphine/naloxone combination (Suboxone). However, a study released yesterday suggested the combination buprenorphine/naloxone product was as safe (if not safer) than the buprenorphine only product  https://lnkd.in/eQF9-ZZ9

Treating opioid use disorder (OUD) in pregnancy is something many providers are uncomfortable doing. The fact is, OUD isn’t going anywhere, so we need to educate ourselves on evidence-based care for this population. Massachusetts General Center for Women’s Health published new research comparing the safety of using buprenorphine (Subutex) or buprenorphine-naloxone (Suboxone) alone to treat OUD during pregnancy. Findings of note: 1. No significant difference in maternal morbidity, major congenital malformations, low birth weight, preterm birth, respiratory problems or delivery by c-section. 2. The risk of Neonatal Abstinence Syndrome was a significantly lower in infants exposed to buprenorphine with naloxone compared to those exposed to buprenorphine alone (37.4% vs 55.8%, respectively). This is a good argument for prescribing Suboxone vs Subutex during pregnancy.

📢 Original article Sharing-Vol. 51 No. 9 💕 Title: The Effect of Folic Acid Supplementation in the First Trimester of Pregnancy on Perinatal Outcomes: A Retrospective Cohort Study 🤵 Authors: Dilay Gök Korucu,*, Aylin Önder Dirican 🔔 Full Text: https://lnkd.in/gQCMrSGw 🔑 Keywords: folic acid first trimester gestational diabetes mellitus perinatal outcome #OBGYN #WomensHealth #Gynecology #WomensWellness  #ReproductiveHealth #MaternalHealth #GynecologicalCancer  #Oncology #OvarianTumor #SurgicalOncology  #clinicalresearch #PerinatalMentalHealth #MaternalMentalHealth #PostnatalDepression  #WomenHealth #Motherhood #Psychology  #PerinatalCare #MentalHealthAParenting #HealthcareProfessionals

A shift in testing for and managing gestational diabetes mellitus (GDM) to much earlier in pregnancy (before 14 weeks) can prevent health complications for both the mother and baby, according to a new series published in The Lancet. Series authors challenge the current approach to GDM management—which focuses on late GDM (24 weeks+)—and call for better detection and prevention efforts alongside a personalized, integrated life-course approach for those who experience or are at risk for GDM.

NPs play a pivotal role in caring for pregnant people. This article provides an overview of gestational and postpartum thyroid disorders, including their assessment, management, and indications for referral. The goal of this article is to help providers better assess and manage #thyroiddisorders during pregnancy and improve patient outcomes. #APRNs #NursePractitioners https://ow.ly/8tFq50SKqVs

🔬 New Systematic Review: Antipsychotic Drug Use During Pregnancy 🔬 Volume 22, Issue 14, 2024 Published: 17 May 2024 📝 Key Findings: • Thorough Review: An extensive review of 38 studies addressing the impact of antipsychotic medications on pregnancy outcomes. • Teratogenicity Insights: Most studies indicate that second-generation antipsychotics do not show significant teratogenic effects or increased malformation rates. • Expert Recommendations: Despite some inconclusive results, the majority of findings suggest that the benefits of continuing antipsychotic medication during pregnancy outweigh potential risks, with no clear need to discontinue treatment. • Resourceful Databases: Studies from Boston and Northern European registers provided valuable insights into the safety of psychiatric drugs during pregnancy. 🔍 Explore the Full Review to understand the implications of antipsychotic use during pregnancy and its impact on maternal and infant health. 🔗 Read the Article: https://bit.ly/4dOeKM1 💬 Share Your Thoughts: How do you balance the need for antipsychotic medication with the potential risks during pregnancy? #Antipsychotics #PregnancySafety #Teratogenicity #MentalHealth #Pharmacology #SystematicReview

Long acting extended release naltrexone (XR-NTX) is not currently recommended for use during pregnancy due to limited pharmacokinetic and safety data. In this physiologically based pharmacokinetic (PBPK) model, we describe the pharmacokinetics of XR-NTX during pregnancy, as well as predicting dosing recommendations. Babajide Shenkoya Mathangi Gopalakrishnan https://lnkd.in/eTAwiXVN #johnshopkins #harvard #pregnancy #systematicreview #metaanalysis #linkedinfamily #medicine #management #obstetrics #innovation #strategy #networking #health #healthcare #humanresources #digitalmarketing #technology #creativity #future